Pharmacological solutions for vitiligo: emerging role of Janus kinase inhibitors
Authors:
- 17 September 2026
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 27 (14) , 1565-1580
Abstract
1. Vitiligo is a chronic autoimmune pigmentary disorder characterized by the selective loss of melanocytes, resulting in well-demarcated depigmented patches of the skin and hair. Melanocytes, deriv...Keywords
This publication has 96 references indexed in Scilit:
- Oral JΑΚ Inhibitors in Vitiligo TreatmentDermatology and Therapy, 2026
- Apoptosis, inflammation, and oxidative/nitrosative stress-related miRNA expression in vitiligo patientsIrish Journal of Medical Science (1971 -), 2025
- Cancer Risk in Vitiligo: No Evidence of Increased Prevalence—A Systematic Review and Meta-analysisDermatology and Therapy, 2025
- A Comparative Analysis Dissecting the Immune Landscape of Vitiligo and Melanoma from a single-cell Perspective: Two Sides of the Same Coin?Inflammation, 2025
- A retrospective analysis of the efficacy and safety of oral tofacitinib in active vitiligo treatmentArchives of Dermatological Research, 2025
- Efficacy and Safety of Janus Kinase Inhibitors in Patients with Vitiligo: A Systematic Review and Meta‐AnalysisClinical Pharmacology & Therapeutics, 2024
- Mechanisms of melanocyte death in vitiligoMedicinal Research Reviews, 2020
- Vitiligo, From Physiopathology to Emerging Treatments: A ReviewDermatology and Therapy, 2020
- Vitiligo and Melanoma-Associated Vitiligo: Understanding Their Similarities and DifferencesAmerican Journal of Clinical Dermatology, 2020
- Tofacitinib Citrate for the Treatment of VitiligoJAMA Dermatology, 2015